2019 International Congress » Huntington’s Disease

Date: Monday, September 23, 2019

Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Meeting: 2019 International Congress

1:45pm-3:15pm: 7,8- Dihydroxyflavone prevents 3-NitropropionicAcid (3-NP)-induced Striatal Toxicity by Modulating the TrkB receptor and Microglial Activation Pathway

S. Ahmed, M. Kwatra, VGM. Naidu (Kamrup, India)

1:45pm-3:15pm: A global survey on speech language therapists’ awareness to Huntington’s disease

A. Nuzzi, S. Naor, N. Inbar, T. Gurevich, Y. Manor (Santeramo In Colle, Italy)

1:45pm-3:15pm: A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington’s disease

S. Tabrizi, B. Leavitt, P. Sanwald Ducray, E. Wild, V. Schlegel, G. Hooper, A. Nicotra, J. Chevure, A. Smith, R. Lane, F. Bennett, L. Boak, R. Doody, S. Schobel (London, United Kingdom)

1:45pm-3:15pm: A Unified Staging System for Prodromal and Manifest Huntington’s disease

A. Mohan, Z. Sun, S. Ghosh, Y. Li, Y. Cheng, J. Hu, C. Sampaio (Yorktown Heights, NY, USA)

1:45pm-3:15pm: Ancillary Service Utilization and Impact in Huntington’s Disease

J. Yomtoob, C. Yeh, D. Bega (Chicago, IL, USA)

1:45pm-3:15pm: Assessment of Caregiver Burden in Huntington’s disease

M. Yu, K. Tan, K. Koloms, D. Bega (Chicago, IL, USA)

1:45pm-3:15pm: Assessment of Gait in Huntington’s disease patients using EncephaLog smartphone’s application

NI. Inbar, N. Omer, A. Bar David, N. Geva, I. Dabakarov, L. Barsky, Z. Yekutieli, N. Giladi, T. Gurevich (Tel Aviv, Israel)

1:45pm-3:15pm: Brain MRI Volume Changes after 12 months laquinimod treatment of Huntington disease (LEGATO-HD)

R. Reilmann, M. Gordon, A. Feigin, K. Anderson, S. Tabrizi, B. Leavitt, J. Stout, P. Piccini, N. Hobbs, R. Manber, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Victoria, Australia)

1:45pm-3:15pm: Burden of Huntington’s disease in the US: Analysis of an insured population

K. Raimundo, J. Luo, R. Tan, T. To, R. Fuller, J. Warner (South San Francisco, CA, USA)

1:45pm-3:15pm: Can we hear pathology in premanifest Huntington’s disease? Acoustic and listener-based analysis of speech

J. Chan, C. Shirbin, J. Stout, A. Vogel (Melbourne, Australia)

1:45pm-3:15pm: Cerebellar Ataxia in Patients with Huntington’s Disease, an underestimated symptom?

GLF. Franklin, HAT. Teive, FBG. Germiniani, SR. Raskin, GMP. Pavanelli, SSM. Milano, NSL. Lima, OPB. Barsottini, JLP. Pedroso, FAM. Maggi, VT. Tumas, PMC. Carvalho, PCA. Azevedo, ILC. Lopes-Cendes (Curitiba, Brazil)

1:45pm-3:15pm: Changes in GABAergic transmission of striatal neurons in presymptomatic Huntington’s Disease

M. Treven, F. Zirpel, I. Mody (Vienna, Austria)

1:45pm-3:15pm: Characterization of impulsivity in Colombian patients with Huntington’s disease

L. Colmenares, C. Rodriguez, W. Fernandez (Bogotá, Colombia)

1:45pm-3:15pm: Comorbidities and medications in Huntington’s disease, Parkinson’s disease and the general population in a US claims database

L. Ishihara, E. Wild, D. Oliveri (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm: Correlation between structural neuroimaging and clinical outcomes in a small sample of patients with early Huntington’s disease

C. Estevez Fraga, E. Johnson, F. Rodrigues, P. Zeun, N. Hobbs, E. Rees, R. Roos, B. Landwehrmeyer, A. Durr, S. Gregory, R. Scahill, G. Rees, S. Tabrizi (London, United Kingdom)

1:45pm-3:15pm: Digital monitoring of Huntington’s disease with smartphone and smartwatch wearable technology: The Digital-HD study

R. Tortelli, T. Kilchenmann, F. Rodrigues, L. Byrne, A. Bamdadian, F. Lipsmeier, S. Schobel, M. Lindemann, E. Wild (London, United Kingdom)

1:45pm-3:15pm: Electroconvulsive Therapy (ECT): An Effective Option for the Treatment of Medication-Resistant Psychiatric Symptoms in Huntington’s Disease: A Case Series and Review of the Literature

J. Adrissi, N. Nadkarni, E. Gausche, D. Bega (Chicago, IL, USA)

1:45pm-3:15pm: Exploring the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD

B. Leavitt, A. Vallès, A. Stam, C. Brouwers, V. Fodale, A. Bresciani, A. Hill, A. Yung, B. Russell-Schulz, P. Kozlowski, A. Mackay, D. Ma, F. Beg, J. Higgins, S. van Deventer, M. Evers, P. Konstantinova (Vancouver, BC, Canada)

1:45pm-3:15pm: Factors underlying reduced aerobic capacity in Huntington disease

A. Rao, S. Norris, J. Montes, P. Wasserman, K. Marder (New York, NY, USA)

1:45pm-3:15pm: Gene Expression Profiling of depression in Huntington’s disease

G. Colpo, N. Rocha, E. Furr Stimming, A. Lucio (Houston, TX, USA)

1:45pm-3:15pm: Grey-matter volume changes underpinning irritability and aggression in early manifest Huntington’s disease

S. Martinez-Horta, F. Sampedro, J. Perez-Perez, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm: Homozygous Huntington’s disease with two reduced penetrance alleles: A Case Report

K. Grimm, C. Zühlke, C. Gerloff, S. Zittel (Hamburg, Germany)

1:45pm-3:15pm: Huntington’s Disease Protein Huntingtin Associates with its own mRNA

M. Rakhimova, M. Daropova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Huntington’s disease: A case review of Sub-Saharan Africans with diverse origins

M. Muthinja, J. Hooker (Nairobi, Kenya)

1:45pm-3:15pm: Impact of caring for patients with Huntington’s disease on work status

K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (San Francisco, CA, USA)

1:45pm-3:15pm: Insomnia as clinical onset symptom in Juvenile Huntington’s Disease: Evaluation of a Family

M. Gultekin (Kayseri, Turkey)

1:45pm-3:15pm: Intermediate CAG repeat length in the HTT gene and comorbidity – The SHAPE Study (Swedish-Huntingtin-Alleles-and-PhenotypE)

M. Ghazarian, E. Stattin, J. Sundblom, V. Niemelä (Uppsala, Sweden)

1:45pm-3:15pm: Involuntary movements with abnormal brain imaging: A Case Report

W. Webb, P. Chapman, V. Sung, M. Dean (Birmingham, AL, USA)

1:45pm-3:15pm: Magnetic Resonance Spectroscopy Evaluation of Neuronal Integrity and Astrocytosis in a Phase 2 Study of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)

B. Leavitt, R. Reilmann, M. Gordon, K. Anderson, A. Feigin, S. Tabrizi, J. Stout, P. Piccini, B. Russell-Schulz, A. Mackay, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Vancouver, BC, Canada)

1:45pm-3:15pm: Mobility Impairments in Huntington’s Disease due to Cognitive Dysfunction

M. Rakhimova, N. Yusupova (Tashkent, Uzbekistan)

1:45pm-3:15pm: MRI, Clinical, and Neuropathological Findings after Bilateral Intra-striatal Administration of rAAV5-miHTT in Non-human Primates

J. Higgins, B. Blits, L. Spronck, A. Valles-Sanchez, M. Evers, S. van Deventer, P. Konstantinova, M. de Haan (Lexington, MA, USA)

1:45pm-3:15pm: Multimodal characterization of the visual network in Huntington’s disease

O. Odish, S. Gregory, I. Mayer, J.. Mills, E. Johnson, R. Scahill, J. Rothwell, G. Rees, J. Long, S. Tabrizi, R. Roos, M. Orth (Leiden, Netherlands)

1:45pm-3:15pm: NBIA-like MRI findings in a patient with Huntington’s disease

T. Shimizu, T. Matsukawa, Y. Abe, H. Suga, N. Tominaga, M. Nagai, T. Iizuka, H. Ishiura, J. Mitsui, S. Tsuji, R. Hanajima, K. Nishiyama (Yonago, Japan)

1:45pm-3:15pm: Neuromelanin MRI detects monoaminergic cell loss in Huntington Disease Expansion Gene Carriers.

ER. de Natale, H. Wilson, G. Dervenoulas, F. Niccolini, SJ. Tabrizi, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Neuroprotective and neurotrophic efficacy of Ginkgo biloba extracts against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease

P. Kashyap, S. Gupta (Darbhanga, India)

1:45pm-3:15pm: Normative Curves for Selected Unified Huntington Disease Rating Scale Measures

J. Mills, J. Long, A. Mohan, J. Ware, C. Sampaio (Iowa City, IA, USA)

1:45pm-3:15pm: Novel exploratory outcome assessments in GENERATION HD1

D. Trundell, S. Schobel, R. Roos, K. Anderson, A. Thobhani, G. Hooper, M. Nguyen, S. Tabrizi (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm: Patient and physician perspectives on the care and assistance needs in Huntington’s disease

K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (South San Francisco, CA, USA)

1:45pm-3:15pm: Prevalence of Huntington’s Disease in Sardinia, Italy

A. Muroni, MR. Murru, T. Ercoli, V. Melas, E. Casaglia, M. Melis, E. Cocco, G. Defazio (Cagliari, Italy)

1:45pm-3:15pm: Quantification of regional iron content with Susceptibility Weighted Imaging in Huntington Disease Expansion Gene Carriers

ER. de Natale, H. Wilson, G. Dervenoulas, F. Niccolini, SJ. Tabrizi, M. Politis (London, United Kingdom)

1:45pm-3:15pm: Quantitative Motor (Q-Motor) Assessments Suggest a Beneficial Central Effect of Laquinimod in a Phase II Study in Huntington Disease (LEGATO-HD)

R. Reilmann, M. Gordon, R. Schubert, K. Anderson, A. Feigin, S. Tabrizi, B. Leavitt, J. Stout, P. Piccini, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Muenster, Germany)

1:45pm-3:15pm: Reliability, feasibility and validity of a novel digital monitoring platform assessing cognitive and motor symptoms in people with Stage I and II Huntington’s disease (HD)

F. Lipsmeier, C. Simillion, A. Atieh Bamdadian, A. Smith, S. Schobel, C. Gossens, P. Weydt, E. Wild, M. Lindemann (Basel, Switzerland)

1:45pm-3:15pm: Seeking regulatory feedback on novel clinical outcome assessments: a case example from the Huntington’s Disease – Regulatory Science Consortium (HD-RSC)

A. Mullin, R. Fuller, G. Stebbins, J. Stout, A. Robbins, P. Feigenbaum, M. Roche, E. Gantman, C. Sampaio, M. Brumfield (Tucson, AZ, USA)

1:45pm-3:15pm: Speech impairment as a marker of clinical changes in premanifest Huntington’s disease

J. Chan, Y. Lie, J. Stout, A. Vogel (Melbourne, Australia)

1:45pm-3:15pm: Subcortical atrophy is an early event in Huntington’s disease

N. Rocha, L. Latham, O. Charron, G. Papadimitropoulos, G. Colpo, L. Freeman, E. Furr Stimming, A. Teixeira (Houston, TX, USA)

1:45pm-3:15pm: Successful altruistic living kidney donation in a patient with Huntington’s disease

C. Cooper, S. Chen, B. Bernard, J. Goldman (Chicago, IL, USA)

1:45pm-3:15pm: Sustained mutant huntingtin lowering in the brain and cerebrospinal fluid of Huntington disease minipigs mediated by AAV5-miHTT gene therapy

A. Vallès-Sanchez, A. Stam, C. Brouwers, J. Klíma, B. Bohuslavová, R. Pintauro, M. Sogorb-Gonzalez, L. Paerels, V. Fodale, A. Bresciani, Z. Ellederová, B. Blits, J. Motlik, S. van Deventer, M. Evers, P. Konstantinova (Amsterdam, Netherlands)

1:45pm-3:15pm: The Huntington’s Disease-Behavioral Questionnaire (HD-BQ): A New Screening Tool for Behavioral Disturbances in HD

J. Corey-Bloom, S. Aboufadel, I. Beltran-Najera, C. Snell, M. Williams, P. Gilbert (La Jolla, CA, USA)

1:45pm-3:15pm: The Roche HD Natural History Study – an external comparator by design

G. Hooper, G. Palermo, F. Hlavac, C. Finnegan, E. Frick, L. Boak, R. Doody, S. Schobel (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm: Translating Preclinical Data to a Human Equivalent Dose for AMT-130 AAV Gene Therapy for Early Manifest Huntington’s Disease

M. Evers, M. de Haan, A. Valles-Sanchez, E. Sawyer, S. Gill, R. Roos, S. van Deventer, P. Konstantinova, J. Higgins (Amsterdam, Netherlands)

1:45pm-3:15pm: Tumor Pathology in Patients with Huntington’s Disease in a Specialized Center of Buenos Aires, Argentina (Preliminary Data)

D. Dias, E. Gatto, J. Etcheverry, M. Cesarini, G. da Prat, F. Peralta Calderon (Capital Federal, Argentina)

1:45pm-3:15pm: Usefulness of Heart Rate Variability to Identify the Risk of Falling in Huntington’s Disease

C. Terroba-Chambi, D. Vigo, M. Merello (Buenos Aires, Argentina)

1:45pm-3:15pm: Using functional status to aid interpretation of cUHDRS scores in patients with Huntington’s disease

D. Trundell, G. Palermo, J. Long, B. Leavitt, S. Schobel, S. Tabrizi (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm: What connectivity tells us about neurodegeneration in Huntington disease? A fMRI study

P. de Azevedo, M. Nogueira, L. Ribeiro, B. de Campos, R. Guimarães, L. Piovesana, F. Cendes, I. Lopes-Cendes, C. Yasuda (Campinas, Brazil)

« View all sessions from the 2019 International Congress.